Biogen | BIIB - Выручка от реализации





Продажи Изменить Дата
AbbVie USD 17.4B 410M 2026-09
Acadia Pharmaceuticals USD 342M 34.04M 2026-09
ALKERMES USD 480.13M 15.88M 2026-09
Amgen USD 10.4B 300M 2026-09
Bayer EUR 10.05B 820M 2026-09
Biogen USD 2.8B 60M 2026-09
BioMarin Pharmaceutical USD 1.03B 40M 2026-09
Bristol-Myers Squibb USD 13.07B 100M 2026-09
Eli Lilly USD 24.4B 1.43B 2026-09
Gilead Sciences USD 8.3B 500M 2026-09
Incyte USD 1.56B 110M 2026-09
Merck USD 18.1B 1.5B 2026-09
Moderna USD 1.31M 98.69M 2026-09
Neurocrine Biosciences USD 1.12B 161M 2026-09
Novartis USD 14.52B 112M 2026-09
Pfizer USD 16.6B 1.57B 2026-09
PTC Therapeutics USD 357.8M 3.2M 2026-09
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 5.12B 830M 2026-09
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 14.44B 2.49B 2026-09
Sanofi EUR 12.3B 160M 2026-06
Sarepta Therapeutics USD 381.4M 19.9M 2026-09
Teva Pharmaceutical Industries USD 4.37B 8.3B 2026-09
Ultragenyx Pharmaceutical USD 173M 41M 2026-09
United Therapeutics USD 832.5M 49.2M 2026-09
Vertex Pharmaceuticals USD 3.44B 110M 2026-09